FGF21 gene therapy as treatment for obesity and insulin resistance
FGF21 gene therapy as treatment for obesity and insulin resistance
About this item
Full title
Author / Creator
Jimenez, Veronica , Jambrina, Claudia , Casana, Estefania , Sacristan, Victor , Muñoz, Sergio , Darriba, Sara , Rodó, Jordi , Mallol, Cristina , Garcia, Miquel , León, Xavier , Marcó, Sara , Ribera, Albert , Elias, Ivet , Casellas, Alba , Grass, Ignasi , Elias, Gemma , Ferré, Tura , Motas, Sandra , Franckhauser, Sylvie , Mulero, Francisca , Navarro, Marc , Haurigot, Virginia , Ruberte, Jesus and Bosch, Fatima
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic agent for T2D/obesity. Native FGF21 has, however, poor pharma...
Alternative Titles
Full title
FGF21 gene therapy as treatment for obesity and insulin resistance
Authors, Artists and Contributors
Author / Creator
Jambrina, Claudia
Casana, Estefania
Sacristan, Victor
Muñoz, Sergio
Darriba, Sara
Rodó, Jordi
Mallol, Cristina
Garcia, Miquel
León, Xavier
Marcó, Sara
Ribera, Albert
Elias, Ivet
Casellas, Alba
Grass, Ignasi
Elias, Gemma
Ferré, Tura
Motas, Sandra
Franckhauser, Sylvie
Mulero, Francisca
Navarro, Marc
Haurigot, Virginia
Ruberte, Jesus
Bosch, Fatima
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5049632ea9d54bcabb730fd40ac11d0c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5049632ea9d54bcabb730fd40ac11d0c
Other Identifiers
ISSN
1757-4676
E-ISSN
1757-4684
DOI
10.15252/emmm.201708791
